儿童再生障碍性贫血造血干细胞移植相关并发症

doi:10.12372/jcp.2022.22e1706

摘要/Abstract

摘要：

再生障碍性贫血(AA)是一种骨髓造血衰竭性疾病，主要表现为骨髓造血功能低下、全血细胞减少和贫血/出血/感染征候群。异基因造血干细胞移植是治疗重型AA的重要手段。移植相关并发症的发生及管理仍是临床一巨大挑战，其预防和治疗可直接影响移植的效果、患儿长期的生存及生活质量。文章对AA患儿造血干细胞移植过程中常见移植并发症的诊断、预防及治疗进展予以阐述，以期提高患儿移植成功率及生存率。

关键词: 再生障碍性贫血, 异基因造血干细胞移植, 并发症, 儿童

Abstract:

Aplastic anemia (AA) is a bone marrow hematopoietic failure disorder that is characterized by low bone marrow hematopoiesis, complete blood cytopenia and anemia/hemorrhage/infection syndrome. Allogeneic hematopoietic stem cell transplantation is currently an important method in the treatment of severe AA. The occurrence and management of transplant-related complications remain a great clinical challenge, and their prevention and treatment can directly affect the outcome of transplantation, long-term survival and quality of life of the children. In this paper, we review the diagnosis, prevention and treatment of common transplant complications during HSCT in children with AA, with the aim of improving the success rate and survival rate of these transplanted children.

Key words: aplastic anemia, allogeneic hematopoietic stem cell transplantation, complication, child

徐佳伟, 金润铭. 儿童再生障碍性贫血造血干细胞移植相关并发症[J]. 临床儿科杂志, 2023, 41(3): 175-180.

XU Jiawei, JIN Runming. Research progress in complications related to hematopoietic stem cell transplantation in children with aplastic anemia[J]. Journal of Clinical Pediatrics, 2023, 41(3): 175-180.

图/表 1

参考文献 41

[1]	Young NS. Aplastic anemia[J]. N Engl J Med, 2018, 379(17): 1643-1656. doi: 10.1056/NEJMra1413485
[2]	中华医学会血液学分会红细胞疾病贫血学组. 再生障碍性贫血诊断与专家共识(2017年版)[J]. 中华血液学杂志, 2017, 38(1): 1-5.
[3]	史红鱼, 程翼飞, 黄晓军, 等. 儿童单倍型造血干细胞移植后巨细胞病毒感染临床分析[J]. 中华血液学杂志, 2019, 40(5): 426-428.
[4]	中华医学会血液学分会干细胞应用学组. 异基因造血干细胞移植患者巨细胞病毒感染管理中国专家共识(2022年版)[J]. 中华血液学杂志, 2022, 43(8): 617-623.
[5]	黄晓军, 许兰平, 任汉云, 等. 异基因造血干细胞移植后巨细胞病毒病及其危险因素分析[J]. 中华医学杂志, 2003, 83(9): 766-769.
[6]	Khoury HJ, Wang T, Hemmer MT, et al. Improved survival after acute graft-versus-host disease diagnosis in the modern era[J]. Haematologica, 2017, 102(5): 958-966. doi: 10.3324/haematol.2016.156356 pmid: 28302712
[7]	Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD[J]. Blood, 2009, 114(3): 702-708. doi: 10.1182/blood-2009-03-208983 pmid: 19470693
[8]	Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation[J]. Blood, 1998, 92(7): 2303-2314. pmid: 9746768
[9]	中华医学会血液学分会造血干细胞应用学组, 中国抗癌协会血液病转化委员会. 慢性移植物抗宿主病(cGVHD)诊断与治疗中国专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(4): 11.
[10]	Firoz BF, Lee SJ, Nghiem P, et al. Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis[J]. Arch Dermatol, 2006, 142(2): 175-182. pmid: 16490845
[11]	Levine JE, Braun TM, Harris AC, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study[J]. Lancet Haematol, 2015, 2(1): e21-e29. doi: 10.1016/S2352-3026(14)00035-0
[12]	中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅲ)——急性移植物抗宿主病(2020年版)[J]. 中华血液学杂志, 2020, 41(7): 529-536.
[13]	Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease[J]. N Engl J Med, 2021, 385(3): 228-238. doi: 10.1056/NEJMoa2033122
[14]	韩明哲. 异基因造血干细胞移植后植入功能不良研究进展[J]. 临床血液学杂志, 2019, 32(9): 660-664.
[15]	Sun YQ, He GL, Chang YJ, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation[J]. Ann Hematol, 2015, 94(10), 1699-1705. doi: 10.1007/s00277-015-2440-x
[16]	师辰燕, Mamal A, 刘增慧, 等. 重型再生障碍性贫血行异基因造血干细胞移植后植入功能不良的危险因素分析[J]. 中华血液学杂志, 38(9): 761-766.
[17]	Lin F, Han T, Zhang Y, et al. The incidence, outcomes, and risk factors of secondary poor graft function in haploidentical hematopoietic stem cell transplantation for acquired aplastic anemia[J]. Front Immunol, 2022, 9: 896034.
[18]	Kong Y, Chang YJ, Wang YZ, et al. Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2013, 19(10): 1465-1473. doi: 10.1016/j.bbmt.2013.07.014
[19]	Hassan HT, Krog C, Stockschläder M, et al. Factors influencing haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis. A single-centre experience[J]. Support Care Cancer, 1997, 5(4): 299-306. pmid: 9257426
[20]	王佳丽, 韩明哲. 异基因造血干细胞移植后植入功能不良发生机制研究进展[J]. 中华血液学杂志, 2019, 38(9): 792-794.
[21]	Olivieri J, Mancini G, Goteri G, et al. Reversal of poor graft function with iron-chelating therapy after allogeneic transplantation for severe aplastic anemia[J]. Leuk Lymphoma, 2016, 57(4): 965-968. doi: 10.3109/10428194.2015.1085530
[22]	Visani G, Guiducci B, Giardini C, et al. Deferasirox improves hematopoiesis after allogeneic hematopoietie SCT[J]. Bone Marrow Transplant, 2014, 49(4): 585-587. doi: 10.1038/bmt.2013.213
[23]	Zhao Y, Gao F, Shi J, et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(9): 1898-1907. doi: 10.1016/j.bbmt.2019.05.036
[24]	Torok-Storb B, Boeckh M, Hoy C, et al. Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation[J]. Blood, 1997, 90(5): 2097-2102. pmid: 9292549
[25]	Kong Y. Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights[J]. Semin Hematol, 2019, 56(3): 215-220. doi: S0037-1963(18)30143-4 pmid: 31202433
[26]	Dvorak CC, Higham C, Shimano KA. Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management[J]. Front Pediatr, 2019, 7: 133. doi: 10.3389/fped.2019.00133 pmid: 31024873
[27]	中华医学会血液学分会造血干细胞应用学组. 造血干细胞移植相关血栓性微血管病诊断和治疗中国专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(3): 177-184.
[28]	Epperla N, Li A, Logan B, et al. Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy[J]. Br J Haematol, 2020, 189(6): 1171-1181. doi: 10.1111/bjh.16457
[29]	Jodele S, Davies SM, Lane A, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults[J]. Blood, 2014, 124(4): 645-653. doi: 10.1182/blood-2014-03-564997 pmid: 24876561
[30]	Laskin BL, Goebel J, Davies SM, et al. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy[J]. Blood, 2011, 118(6): 1452-1462. doi: 10.1182/blood-2011-02-321315 pmid: 21596850
[31]	Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury[J]. Blood Rev, 2015, 29(3): 191-204. doi: 10.1016/j.blre.2014.11.001 pmid: 25483393
[32]	钱晓文, 翟晓文. 造血干细胞移植相关血栓性微血管病[J]. 中国小儿急救医学, 2022, 29(8): 577-583.
[33]	Harkensee C, Vasdev N, Gennery AR, et al. Prevention and management of BK-virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation--a systematic review and evidence-based guidance for clinical management[J]. Br J Haematol, 2008, 142(5): 717-731. doi: 10.1111/j.1365-2141.2008.07254.x
[34]	Hayden RT, Gu Z, Liu W, et al. Risk factors for hemorrhagic cystitis in pediatric allogeneic hematopoietic stem cell transplant recipients[J]. Transpl Infect Dis, 2015, 17(2): 234-241. doi: 10.1111/tid.12364 pmid: 25648430
[35]	Shepherd JD, Pringle LE, Barnett MJ, et al. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow trans-plantation[J]. J Clin Oncol, 1991, 9(11): 2016-2020. pmid: 1941060
[36]	Fu H, Xu L, Liu D, et al. Late-onset hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation in patients with advanced leukemia: differences in ATG dosage are key[J]. Int J Hematol, 2013, 98(1): 89-95. doi: 10.1007/s12185-013-1350-8 pmid: 23632950
[37]	Xu LP, Zhang HY, Huang XJ, et al. Hemorrhagic cystitis following hematopoietic stem cell transplantation: incidence, risk factors and association with CMV reactivation and graft-versus-host disease[J]. Chin Med J (Engl), 2007, 120(19): 1666-1671.
[38]	Olson A, Lin R, Marin D, et al. Third-Party BK virus-specific cytotoxic T lymphocyte therapy for hemorrhagic cystitis following allotransplantation[J]. J Clin Oncol, 2021, 39(24): 2710-2719. doi: 10.1200/JCO.20.02608
[39]	Saade A, Styczynski J, Cesaro S, et al. BK virus infection in allogeneic hematopoietic cell transplantation: an update on pathogenesis, immune responses, diagnosis and treatments[J]. J Infect, 2020, 81(3): 372-382. doi: S0163-4453(20)30390-X pmid: 32526327
[40]	Petca RC, Popescu RI, Toma C, et al. Chemical hemo-rrhagic cystitis: diagnostic and therapeutic pitfalls (Review)[J]. Exp Ther Med, 2021, 21(6): 624. doi: 10.3892/etm.2021.10056
[41]	何云燕. 造血干细胞移植后出血性膀胱炎的诊疗[J]. 临床儿科杂志, 2022, 40(1): 8-13.